Warning letter
Zhejiang Huahai Pharmaceutical: warning letter of Nov 29, 2018
FDA warning letter 566685 · Center for Drug Evaluation and Research
Key facts
| Reference number | 566685 |
|---|---|
| Company | Zhejiang Huahai Pharmaceutical |
| Subject | Zhejiang Huahai Pharmaceutical,CGMP/Active Pharmaceutical Ingredient (API)/Adulterated |
| Issue date | Nov 29, 2018 |
| Posted date | Dec 11, 2018 |
| Issuing office | Center for Drug Evaluation and Research |
| Product type | Drugs |
| Inspection city | Linhai |
| Inspection start date | Jul 23, 2018 |
| Letter on fda.gov | fda.gov |
At a glance
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: